Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10590098 | 1.00 | CYP3A4 (0.39) | CYP3A4MAPK1SIRT1CHRNB2SLC6A2 | |
| SCHEMBL998716 | 0.74 | CHRNB2 (0.39) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5335969 | 0.74 | CHRNB2 (0.39) | CYP3A4MAPK1CHRNB2SLC6A2CHRNB4 | |
| SCHEMBL8007579 | 0.74 | MAPK1 (0.70) | CYP3A4MAPK1SIRT1CHRNB2SLC6A2 | |
| SCHEMBL8538968 | 0.74 | MAPK1 (0.70) | CYP3A4MAPK1SIRT1CHRNB2SLC6A2 | |
| SCHEMBL8538845 | 0.74 | MAPK1 (0.70) | CYP3A4MAPK1SIRT1CHRNB2SLC6A2 | |
| SCHEMBL1730477 | 0.72 | ALDH1A1 (0.41) | SIRT1CHRNB2SLC6A2CHRNB4CHRNA3 | |
| SCHEMBL14572621 | 0.72 | SIRT1 (0.42) | SIRT1SLC6A2ALDH1A1LMNAGAA | |
| SCHEMBL10794880 | 0.71 | ALDH1A1 (0.55) | CYP3A4MAPK1ALDH1A1LMNAGAA | |
| SCHEMBL2748786 | 0.71 | ALDH1A1 (0.55) | CYP3A4MAPK1ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040073045-A1 | Pyrrolidine derivative and process for producing the same | EISAI CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1375479-A9 | PYRROLIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1375465-A1 | CYCLOOCTANONE DERIVATIVE AND CYCLODECANONE DERIVATIVE, AND USE THEREOF | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-0098456-B1 | PEPTIDES COMPRISING A (1S,2R,3R)- OR (1R,2S,3S)-1-NITRILO-1-CARBONYL-3-METHYL-2-OXY-HEPTANE OR -HEPT-5-ENE RESIDUE USEFUL IN THE TOTAL SYNTHESIS OF CYCLOSPORINS, AND PROCESSES FOR THEIR PRODUCTION | SANDOZ AG (CH) | 1989-05-24 | — | — | EP | disclosed |
| EP-0098457-B1 | (1S,2R,3R)- AND (1R,2S,3S)-NITRILO-1-CARBONYL-3-METHYL-2-OXY-HEPTANES AND -HEPT-5-ENES USEFUL IN THE TOTAL SYNTHESIS OF CYCLOSPORINS AND PROCESSES FOR THEIR PRODUCTION | SANDOZ AG (CH) | 1987-08-05 | — | — | EP | disclosed |
| US-4554351-A | STEREOISOMERS | SANDOZ LTD. (CH) | 1985-11-19 | — | — | US | disclosed |
| EP-0034567-B1 | A METHOD FOR THE TOTAL SYNTHESIS OF CYCLOSPORINS AND NOVEL CYCLOSPORINS | SANDOZ AG (CH) | 1984-11-07 | — | — | EP | disclosed |
| US-4396542-A | Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production | SANDOZ LTD. (CH) | 1983-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073045-A1 | Pyrrolidine derivative and process for producing the same | DHPS, SQLE, FDFT1 | CYP3A4 1799/4885MAPK1 2692/4885SIRT1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.